Document:

exv10w23

 

Exhibit 10.23

*** Text Omitted and Filed Separately

Pursuant to a Confidential Treatment Request

Under 17 C.F.R. §§ 200.80(b)(4)

and 240.24b-2

THIRD AMENDMENT TO THE AGREEMENT ENTITLED

“LICENSE AGREEMENT to Hepatitis Virus Immunology and Immunotherapy”

ENTERED INTO SEPTEMBER 23, 1991

BETWEEN THE SCRIPPS RESEARCH INSTITUTE AND CYTEL CORPORATION

This Third Amendment to the agreement entitled “License Agreement to Hepatitis Virus Immunology and
Immunotherapy” (the “Third Amendment”) is entered into and made effective as of July 30, 2005 (the
“Amendment Effective Date”) by and between The Scripps Research Institute, a California nonprofit
public benefit corporation (“TSRI”) located at 10550 North Torrey Pines Road, La Jolla, California
92037, and Epimmune Inc. (“Licensee”), a Delaware corporation located at 5820 Nancy Ridge Drive,
San Diego, California, 92121, with respect to the facts set forth below.

WITNESSETH

WHEREAS, TSRI and Licensee previously entered into that certain License Agreement effective as of
September 23, 1991 (the “Agreement”); and

WHEREAS, TSRI and Licensee previously amended the Agreement by an amendment effective June 17, 1992
(the “First Amendment”); and

WHEREAS, TSRI and Licensee further amended the Agreement by an amendment effective October 12, 1995
(the “Second Amendment”); and

WHEREAS, TSRI and Licensee agreed in the Agreement to amend the Agreement at the time each
sublicense is being negotiated, to set a specific royalty percentage applicable to sublicense
royalties for that sublicense agreement, all as further set forth in the Agreement.

NOW THEREFORE, TSRI and Licensee hereby agree to amend the Agreement as follows:

	 	1.	 	All capitalized terms not defined in this Third Amendment shall have the meaning given
to them in the Agreement.
	 
	 	2.	 	Section 3.5 of the Agreement is hereby amended to add the following sentence to the end
of Section 3.5:
	 
	 	 	 	For clarification, “Sublicense Royalties” exclude any payments made to Epimmune (a) for the
purchase of equity securities at fair market value or as part of a strategic relationship

1

 

	 	 	 	involving significant intellectual property rights of
Epimmune in addition to the Patent Rights, or (b) as funding at cost for research and development activities currently being
conducted by Epimmune personnel.
	 
	 	3.	 	Section 3.5 of the Agreement is hereby amended to include the following additional
paragraph at the end of the Section:

	 	3.5.1	 	Sublicense Royalties for Innogenetics Sublicense. Pursuant to Section 2.2
hereof, Epimmune has granted a sublicense to Genencor International, Inc., which was
effective as of July 9, 2001, and was assigned by Genencor International, Inc. to
Innogenetics, NV (“Innogenetics”) on March 30, 2004, as may be amended (the
“Innogenetics Sublicense”). Pursuant to this Section 3.5 Epimmune and TSRI have agreed
that the following royalty shall be payable on Sublicense Royalties paid to Epimmune
under the Innogenetics Sublicense: (i) Epimmune shall pay to TSRI [...***...] of all
Sublicense Royalties, which are not royalties on Net Sales of Licensed Products,
received by Epimmune pursuant to the Innogenetics Sublicense; and (ii) for Sublicense
Revenues which are royalties on the Net Sales of Licensed Products by Innogenetics or
its sublicensees, Epimmune shall pay (or shall cause Innogenetics to pay) to TSRI an
amount equivalent to [...***...] of what is due to Epimmune from Innogenetics as a royalty
on Net Sales of Licensed Products by Innogenetics and its sublicensees calculated in
accordance with the terms of the Innogenetics Sublicense (but excluding any payment by
Innogenetics to any third party of amounts due under any license agreement between
Epimmune and such third party), without taking into account any offsets or credits
against such amount paid by Innogenetics to Epimmune as a result of the royalty owed to
TSRI, but in no event shall the royalty paid to TSRI on Sublicense Revenues which are
royalties on Net Sales of Licensed Products by Innogenetics and its sublicensees be
less than [...***...] of Net Sales of Licensed Products by Innogenetics and its
sublicensees (calculated in accordance with the terms of the Innogenetics Sublicense).

	 	4.	 	Each party for itself and its respective subsidiaries, related entities, predecessors,
successors, heirs, executors, administrators, officers, directors, agents, employees and
assigns (as applicable), fully and forever releases and discharges the other party and its
respective subsidiaries, related entities, predecessors, successors, heirs, executors,
administrators, officers, directors, shareholders, agents, employees and assigns (as
applicable), with respect to any and all claims, obligations, debts, liabilities and causes
of action, of every nature, kind and description, in law, equity or otherwise, whether
known, unknown, suspected, unsuspected, anticipated or unanticipated, including, without
limitation, any right of termination under the Agreement, arising out of or relating to the
failure to have determined the specific royalty percentage under Section 3.5 of the
Agreement with respect to the Innogenetics Sublicense prior to the date of this Amendment
Effective Date, and each party promises and agrees that it will never sue the other or
otherwise institute or participate in any legal or administrative proceedings against the
other with respect to such failure to have determined the specific royalty percentage under
Section 3.5 of the Agreement with respect

*CONFIDENTIAL TREATMENT
REQUESTED

2

 

	 	 	 	to the Innogenetics Sublicense prior to the date of this Amendment Effective Date. With
respect to the matters released herein, the parties expressly waive any and all rights and
benefits conferred upon them by statute, if any, or common law principle of similar effect
to the effect that general releases do not extend to unsuspected claims, including statutory
language similar to Section 1542 of the Civil Code of the State of California, which states
as follows:

“A general release does not extend to claims which the creditor does
not know or suspect to exist in his favor at the time of executing the
release, which if known by him must have materially affected his
settlement with the debtor.”

	 	 	 	TSRI has relied on the representations of Epimmune regarding amounts due to TSRI
under Section 3.5 of the Agreement. If those representations are in error, then
this Section 3 of the Third Amendment shall be rendered null and void ab initio.
	 
	 	 	 	In addition, if Epimmune fails to make any payments required by Section 3.5 of
the Agreement (and does not cure such failure by making such payment within
thirty (30) days after written notice of the failure from TSRI), this Section 3
of the Third Amendment shall be rendered null and void ab initio.
	 
	 	5.	 	Except as specifically modified or amended hereby, the Agreement as amended by the
First and Second Amendments shall remain in full force and effect and, as so modified or
amended, is hereby ratified, confirmed and approved. No provision of this Third Amendment
may be modified or amended except expressly in writing signed by both parties.
	 
	 	6.	 	In the event of any conflict or inconsistency between the terms of the Agreement as
amended by the First and the Second Amendment, and the terms of this Third Amendment, the
terms of this Third Amendment shall prevail.
	 
	 	7.	 	This Third Amendment, together with the Agreement, the First Amendment, and the Second
Amendment constitutes the entire agreement between the parties with respect to the subject
matter hereof and supersedes any prior written and oral agreements and discussions.
	 
	 	8.	 	This Third Amendment may be executed in counterparts, each of which shall constitute an
original and all of which, when taken together, shall constitute one agreement. This Third
Amendment shall be construed in accordance with, and governed in all respects by, the laws
of the State of California without giving effect to principles of conflicts of laws.
	 
	 	9.	 	This Third Amendment shall terminate ab initio if payment for amounts due as of the
Amendment Effective Date pursuant to Section 3.5 of the Agreement are not received by TSRI
within ten (10) days of the Amendment Effective Date, or by July 31, 2005, whichever is the
first to occur.

3

 

IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives to execute
this Third Amendment.

	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	LICENSEE:

	 	 	 	TSRI:	 	 
	 
	 	 	 	 	 	 
	Epimmune Inc.

	 	 	 	The Scripps Research Institute	 	 
	 
	 	 	 	 	 	 
	/s/ Emile Loria

	 	 	 	/s/ Arnold LaGuardia	 	 
	 

	 	 	 	 	 	 
	Emile Loria, M.D.

President &CEO

	 	 	 	Arnold LaGuardia

Executive Vice President	 	 
	 
	 	 	 	 	 	 
	Date: 7/29/05

	 	 	 	Date: 8/1/05	 	 

4exv10w24

 

Exhibit 10.24

FOURTH AMENDMENT of the LICENSE AGREEMENT

This Fourth Amendment of the License Agreement is made this 28th day of September
2005 (the “Fourth Amendment”) by and between IDM Pharma, Inc. (formerly Epimmune Inc. (hereinafter
referred to as “Epimmune”)), having an office and a place of business at 5820 Nancy Ridge Drive,
San Diego, California 92121 U.S.A (hereinafter referred to as “IDMI”), and Innogenetics N.V.,
having an office and a place of business at Technologiepark 6, B-9052 Ghent, Belgium (hereinafter
referred to as “INNX”), to amend the License Agreement dated July 9, 2001 between IDMI and INNX
(the “Agreement”) as amended by a First Amendment of the License Agreement, dated October 16, 2002
(the “First Amendment”), a Second Amendment of the License Agreement, dated March 15, 2004 (the
“Second Amendment”) and a Third Amendment of the License Agreement, dated March 29, 2004 (the
“Third Amendment”).

WHEREAS :

	•	 	Epimmune and Genencor International, Inc. (“GCOR”) executed the Agreement;
	 
	•	 	Epimmune and GCOR executed the First Amendment and the Second Amendment;
	 
	•	 	GCOR assigned this Agreement, amended as aforesaid, to INNX by virtue of an Assignment and, in that capacity, INNX
replaced GCOR as a signatory to the Agreement;
	 
	•	 	Epimmune and INNX executed the Third Amendment;
	 
	•	 	Epimmune Inc. combined with IDM S.A. and changed its name to IDM Pharma, Inc.; and
	 
	•	 	IDMI and INNX (hereinafter sometimes individually referred to as the “Party” and collectively as the “Parties”) are
desirous of extending the Agreement in scope and duration as specified herein under the following terms and conditions.

NOW THEREFORE, the Parties hereto agree to amend the Agreement, as follows:

	1.	 	The Parties acknowledge that, as of the Effective Date of this Fourth Amendment, references
to EPMN in the Agreement, as amended by the First Amendment, the Second Amendment, the Third
Amendment and this Fourth Amendment, shall be amended so as to replace “EPMN” with “IDMI.”
	 
	2.	 	Section 1.6 shall be amended to read, as follows:

	 	 	 	“1.6 “Collaboration Term” shall mean the five (5) year period from April 2, 2001
through March 30, 2006, unless extended by mutual agreement or terminated early as
provided for in the Collaboration Agreement.”

The Parties hereto further agree, as follows:

	1.	 	Other Terms Remain in Effect. All terms and conditions of the License Agreement, as amended
by the First Amendment and the Second Amendment and the Third Amendment, which are not
modified by this Fourth Amendment, shall remain in full force and effect. From and after the
Effective Date of this Fourth Amendment, for purposes of the License Agreement, the term
“Agreement” shall be deemed to mean the License Agreement, the First Amendment, the Second
Amendment, the Third Amendment and this Fourth Amendment.
	 
	2.	 	Miscellaneous. This Fourth Amendment shall be governed by and construed under the laws of
the State of California as applied to agreements among California residents entered into and
to be performed entirely within California. The provisions hereof shall inure to the benefit
of, and be binding upon, the successors and assigns of Innogenetics and the Company.
	 
	3.	 	Effective Date. This Fourth Amendment shall be effective upon that date on which the last of
the signatures set forth below has been affixed hereto.

1

 

IN WITNESS WHEREOF, the Parties hereto have executed this Amendment in two (2) original copies by
themselves or their duly authorized representatives, as follows:

	 	 	 	 	 
	For Innogenetics N.V.:

	 	 	 	For IDM Pharma, Inc.:
	 
	 	 	 	 
	/s/ Frank Morich

	 	 	 	/s/ Robert De Vaere
	 

	 	 	 	 
	Frank Morich

CEO

Date: 9/28/05

	 	 	 	Robert De Vaere

CFO

Date: 9/28/05
	 
	 	 	 	 
	/s/ Guy Buyens
 

Guy Buyens

Chief Therapeutics Officer

Date: 9/28/05

	 	 	 	 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}]]